Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) was the target of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 99,192 shares, a decrease of 21.0% from the February 12th total of 125,617 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 13,625 shares, the days-to-cover ratio is currently 7.3 days. Based on an average daily volume of 13,625 shares, the days-to-cover ratio is currently 7.3 days. Currently, 0.2% of the shares of the stock are short sold.

Innate Pharma Stock Down 6.0%

NASDAQ:IPHA traded down $0.09 during mid-day trading on Monday, reaching $1.41. The company’s stock had a trading volume of 28,347 shares, compared to its average volume of 15,662. Innate Pharma has a twelve month low of $1.40 and a twelve month high of $2.63. The company’s fifty day simple moving average is $1.71 and its two-hundred day simple moving average is $1.85.

Analysts Set New Price Targets

A number of research firms recently issued reports on IPHA. BTIG Research began coverage on Innate Pharma in a research note on Thursday. They issued a “buy” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Innate Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Hedge Funds Weigh In On Innate Pharma

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in shares of Innate Pharma in the 4th quarter worth about $36,000. OLD Mission Capital LLC acquired a new stake in Innate Pharma during the 4th quarter worth approximately $50,000. Finally, Jane Street Group LLC acquired a new position in Innate Pharma during the fourth quarter valued at approximately $162,000. Institutional investors and hedge funds own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.